A shred of evidence that BCG vaccine may protect against COVID-19: Comparing cohorts in Spain and Italy
Levine, D. I.
Show abstract
IntroductionThere is evidence that the BCG vaccine against tuberculosis also helps prevent other diseases - perhaps including COVD-19. Spain had a program for universal BCG vaccination until 1981. ObjectiveTo see whether cohorts born when Spain had a program of universal BCG vaccination had lower rates of confirmed cases of COVID-19 and mortality (relative to similar cohorts in Italy). MethodsWe compare COVID-19 mortality and confirmed cases for those born roughly a decade before and after 1981. We compare the outcomes to the same age cohorts in Italy, which never had universal BCG vaccination. ResultsThe Spanish cohort that received BCG had a relative risk of 0.962 of having a confirmed case of COVID-19. This risk is statistically significantly below unity (95% CI 0.952 to 0.972, P< 0.001). There is also suggestive evidence the BCG cohort in Spain had lower mortality (relative risk 0.929, CI 0.850 to 1.01, P = 0.11). The small sample size makes this test underpowered. ConclusionThese suggestive results provide a shred of evidence that BCG vaccinations help protect against COVID. I outline many limitations to this study and point how better data can help be more convincing.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- COVID-19 vaccines and evidence-based medicine 91%
- Vaccination or restriction?: COVID-19 vaccine hesitancy and vaccine passports 89%
- The prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up 89%
Similar papers in this journal
- COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 91%
- Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave 90%
- Determinants of the COVID-19 Vaccine Hesitancy Spectrum 90%
Similar papers in this journal
- A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and Myocarditis using Five European Databases 91%
- Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study 91%
- Trends, patterns and psychological influences on COVID-19 vaccination intention: findings from a large prospective community cohort study in England and Wales (Virus Watch) 91%
Similar papers in this journal
- Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohort 90%
- The effect of SARS-CoV-2 testing on healthcare seeking behaviour at primary care level: implications for COVID-19 vaccine effectiveness estimates in test-negative design studies. 90%
- Potential Test-Negative Design Study Bias in Outbreak Settings: Application to Ebola vaccination in Democratic Republic of Congo 88%
Similar papers in this journal
- Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England 91%
- Change in COVID-19 risk over time following vaccination with CoronaVac: A test-negative case-control study 91%
- Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.